Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must be at least 18 years of age
Patients with end-stage renal disease on hemodialysis (including hemodiafiltration) for ≥3 months, receiving dialysis at least 9 hours a week and stable in the view of the investigator
Body weight of at least 50 kg
Male and/or female. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
You may not be if
Recent (\<6 months before screening) clinically significant bleeding
Hemoglobin (Hb) \< 9.0 g/dL at screening
Platelet count \< 100 x 10\^9/L
aPTT or PT \> ULN (upper limit of normal)
Hepatic disease associated with ALT \> 3x ULN, or total bilirubin \>2x ULN with direct bilirubin \> 20% of the total
Receiving anticoagulation in therapeutic doses, other than standard anticoagulation during the hemodialysis procedure
Clareo Health | Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis
